GLP-1 / Incretin Research Peptides

Incretin-class peptides are signalling molecules studied in metabolic and endocrinological research. This category groups the incretin receptor agonists in the catalogue – including dual and triple receptor agonists such as Retatrutide and Tirzepatide – characterised in the literature by agonism at the GLP-1 receptor, with some also engaging the GIP and glucagon receptors. Several are investigational molecules that remain the subject of ongoing published research and are not approved medicines. Supplied for laboratory research only, independently tested to 99%+ purity with a batch COA, dispatched from Western Australia.

How incretin-class compounds are studied. In the published literature this class is characterised through receptor-signalling assays — cAMP accumulation, beta-arrestin recruitment and binding studies at the GLP-1, GIP and glucagon receptors — alongside structural work such as cryo-electron microscopy of receptor complexes and preclinical metabolic models. Analytical laboratories also use these peptides as reference standards when developing HPLC and LC-MS methods for incretin analogues.

Where to start in this category. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist (LY3437943), Tirzepatide a dual GIP/GLP-1 agonist (LY3298176), and Cagrilintide a long-acting amylin analogue studied alongside the incretins. Each has a citation-backed overview — What is Retatrutide?, What is Tirzepatide? and What is Cagrilintide? — and every batch publishes an independent Janoshik Analytical Certificate of Analysis.